# Everolimus in Treating Cutaneous T-cell Lymphoma

> **NCT01637090** · PHASE2 · TERMINATED · sponsor: **Adam Lerner** · enrollment: 3 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01637090
- **Lead sponsor:** Adam Lerner
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2017-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01637090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01637090, "Everolimus in Treating Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01637090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*